So if we look at the uh the NCCN guidelines, um, the section on relapse refractory therapies, um, it does break it down by uh PTCLNOS um subtype as well as T follicular helper subtype, and Um, what we do see is a long list of therapies that are either um approved or used off label or, um, you know, decided as a committee by the NCCN that these um can be considered in this setting. Um, unfortunately, it's not, uh, the list is, um, It's not numbered. So one of the important questions that uh that we are still actively investigating is what is the optimal sequence of the of therapy that we use uh for PTCL but essentially it's long list and develops it and Separately develops it with Romo Depsin are both on that list. Um, in terms of, um, using Develosip and Romodepsin, um, the that data that uh I derived is from, uh, Doctor Horwitz at L and I think it was published in I think it was lancet Oncology, um, but I think you may have to double check me on that. Um, but essentially it, it, it was, it was a phase one study looking at adding uh Romodpsin, um, to Develos it and it was a safe, uh, it was a safety study and looking at also as preliminary efficacy and what we saw in that, in that study was that Um, patients, uh, that, that Romosin when added to Develo, was tolerable, um, and was consistent and in terms of the toxicities it was consistent with the known toxicities of, um, of both Develo and Romodesin. There were no new safety signals and in terms of efficacy, we did see that even though it was a single arm open label study. Um, when compared to historical results, uh, of developed monotherapy, uh, in the primo trial, it did seem Um, that the, uh, the response rates were a little higher, but more importantly, the, the non toxicities of Develo if, for example, colitis, uh, the pneumonitis, um, even, uh, the rashes, um, they, uh, the incidence of those toxicities were less, um, compared to, um, what we saw in, in Primo.
Presenter
